ASURAGEN INCORPORATED
- AUSTIN, TX 78744-1038
- asuragen.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM expiring
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $552.5K
- Awards on record
- 1
- Contract vehicles
- 0
- Verified credentials
- 0
SAM.gov registration expires in 54 days
ASURAGEN INCORPORATED’s registration expires on Jan 7, 2027. Renewal can take weeks; confirm it stays active through proposal submission and award.
View on SAM.gov (opens in a new tab)Learn more about SAM registration and the UEI
About ASURAGEN INCORPORATED
- Headquarters
- AUSTIN, TX 78744-1038
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIE8M9NXN4X4Y7
- CAGE4GGP6
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
- 36-month obligations
- $552.5K
- Awards on record
- 1
- Top funding agencies
- Department of the Army
Awards
W81K0022P0237
Recompete 6–12 mo: Potential end Sep 30, 2027 (10 months away)QUANTIDEX QPCR BCR ABL IS KIT REAGENTS AND QUANTIDEX QPCR BCR-ABL MINOR KIT REAGENTS.
Department of Defense · Department of the Army
- Obligated
- $552.5K
- Period of performance
- Oct 1, 2022 – Sep 30, 2027
| Award | Agency | NAICS · PSC | Obligated | Period of performance | Recompete |
|---|---|---|---|---|---|
W81K0022P0237 QUANTIDEX QPCR BCR ABL IS KIT REAGENTS AND QUANTIDEX QPCR BCR-ABL MINOR KIT REAGENTS. | Department of Defense · Department of the Army | 325413 · 6515MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES | $552.5K | Oct 1, 2022 – Sep 30, 2027 | Recompete 6–12 mo: Potential end Sep 30, 2027 (10 months away)AI brief for award W81K0022P0237Bid team for the recompete of award W81K0022P0237 |
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 23 awards
- Total awarded
- $12,427,799
- By phase
- SBIR Phase I: 17
- SBIR Phase II: 6
- By agency
- Department of Health and Human Services: 23
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2019: 5
- 2018: 3
- 2017: 1
- 2016: 1
- 2015: 3
- 2014: 3
- 2013: 3
- 2012: 1
- 2011: 3
Awards (most recent first)
Novel Strategies for Development of a Multiplexed Test with Expanded Content for Spinal Muscular Atrophy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $182,393
Sep 30, 2019 – Aug 31, 2020
Solicitation PA18-574 (2018) · Topic 102
Novel Strategies for Enhanced Detection of Hemoglobinopathy Carriers
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $231,153
Sep 20, 2019 – Aug 31, 2020
Solicitation PA18-574 (2018) · Topic NHLBI
AmplideX DeepNet, a new paradigm for deep learning analytical tools in the molecular diagnostic space
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $223,058
Sep 15, 2019 – Sep 14, 2020
Solicitation PA18-574 (2018) · Topic 400
Single cell prenatal testing of circulating trophoblasts using a the novel immunomagnetic Micro-Aperture Chip (IMAC) system
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $196,910
Jun 7, 2019 – May 31, 2020
Solicitation PA18-574 (2018) · Topic NICHD
A single test utilizing a unified multiplex PCR/CE workflow targeting five dominant inherited ataxias
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $181,033
May 15, 2019 – Apr 30, 2020
Solicitation PA18-574 (2018) · Topic 103
Novel strategies for enhanced analysis of repeat disorders
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $224,999
Sep 1, 2018 – Aug 31, 2019
Solicitation PA17-302 (2017) · Topic NICHD
Improving rare variant detection in next generation sequencing of liquid biopsies with a molecular barcoding technique that combines a novel primer structure and sophisticated bioinformatics methods
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $224,999
Apr 1, 2018 – Mar 31, 2020
Solicitation PA17-302 (2017) · Topic 400
Development of a unified information-rich test for CNBP and DMPK to improve assessment of Myotonic Dystrophy Type 1 and 2
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $224,978
Apr 1, 2018 – Mar 31, 2020
Solicitation PA16-302 (2016) · Topic 102
Development of a unified Alzheimer s disease test that combines high resolution analysis of TOMM and Apolipoprotein E for improved risk estimates
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $224,984
Apr 15, 2017 – Sep 30, 2019
Solicitation PA16-091 (2016) · Topic NIA
Development of an information rich assay for C ORF as a test for ALS and FTD
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $1,379,750
Sep 30, 2016 – Aug 31, 2019
Solicitation PA15-269 (2015) · Topic 104
Quantitative Superplexing: Single-tube, many-target qPCR for cancer diagnostics
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $246,864
Sep 23, 2015 – Aug 31, 2016
Solicitation PA14-071 (2015) · Topic 102
Development of a reliable and standardized molecular assay for fragile x protein
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $225,000
Sep 18, 2015 – Mar 31, 2017
Solicitation PA14-071 (2015) · Topic NICHD
IGF OT IGF BCR ABL RT QPCR TEST FOR IMPROVED MONITORING OF CML
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2015 · $1,489,494
Solicitation year 2015 · Topic NCI
Integrated Bioinformatics Analysis Suite for targeted NGS of clinical specimens
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2014 · $1,140,126
Sep 28, 2014 – Aug 31, 2016
Solicitation PA13-234 (2014) · Topic 400
Comprehensive Solution for Transcriptome Profiling of Archived Tissues
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $225,000
Solicitation ES13-009 (2014) · Topic NIEHS · Research partner: Stub
Development of an information-rich assay for C9ORF72 as a test for ALS and FTD
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $222,511
Solicitation PA13-234 (2014) · Topic NINDS · Research partner: Stub
Development of clinical triage assay for sepsis management in the Emergency Room
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $314,420
Solicitation PA12-088 (2013) · Topic NIGMS · Research partner: Stub
Enabling use of blood spot cards for accurate high throughput Fragile X screening
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2013 · $2,153,865
Solicitation PA12-088 (2013) · Topic NICHD · Research partner: Stub
SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $241,044
Solicitation year 2013 · Topic NCI · Research partner: Stub
Integrated Bioinformatics Analysis Suite for deep, targeted amplicon sequencing
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $242,940
Solicitation PA11-096 (2012) · Topic NHGRI · Research partner: Stub
Enabling use of blood spot cards for accurate high-throughput Fragile X screening
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $346,302
Solicitation PA10-050 (2011) · Topic NICHD · Research partner: Stub
Technologies for Mapping Interspersed AGG Sequences in the FMR1 Gene
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2011 · $1,329,604
Solicitation PA10-050 (2011) · Topic NICHD · Research partner: Stub
Identification of microRNA Biomarkers for Colon Cancer Recurrence Risk Stratifica
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2011 · $956,372
Solicitation PA09-080 (2011) · Topic NCI · Research partner: Stub
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
No active exclusion on record (checked Nov 14, 2026).
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · as of Nov 14, 2026
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 14, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 14, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 325413Title not in the curated listPrimary
- 325414Biological Product (except Diagnostic) Manufacturing
- 541714Research and Development in Biotechnology (except Nanobiotechnology)
- 621511Medical Laboratories
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
- 6550IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS
- AN13HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
- H165QUALITY CONTROL- MEDICAL, DENTAL, AND VETERINARY EQUIPMENT AND SUPPLIES
PSC names from the Acquisition.gov PSC Manual (opens in a new tab) (April 2025 edition), checked Nov 12, 2026.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with ASURAGEN INCORPORATED?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.